Quest Magazine

ISIS-SMNRx to Be Tested in Phase 3 Trial in Infants With SMA

California-based Isis Pharmaceuticals has announced the opening of a phase 3 clinical trial of its experimental drug ISIS-SMNRx in infants with spinal muscular atrophy (SMA), a muscle-weakening disease that results from loss of nerve cells in the spinal cord.

Safeway Inc. and The Safeway Foundation Fundraising Campaign to Support Programs for People with Disabilities

Jiffy Lube® Supports Fight Against Muscle Disease With Third Annual MUSCLE UP® Campaign

Fire Fighters and MDA Celebrate “60 Years Strong”

DMD: ReveraGen Drug Will Move to Human Testing

ReveraGen BioPharma, based in Silver Spring, Md., is moving ahead with a phase 1 trial of an experimental compound in development to treat Duchenne muscular dystrophy (DMD), made possible by a $2 million grant from U.S.-based MDA and three United Kingdom-based DMD organizations.

International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug

DMD: Eteplirsen Data Still Encouraging at 144 Weeks

Walking ability and respiratory function in boys with Duchenne muscular dystrophy (DMD) show continued benefit from eteplirsen at 144 weeks (almost three years), the drug's developer announced today. In addition, the intravenously infused drug was well tolerated, with no serious treatment-related adverse events seen.

Sarepta Therapeutics Reports Long-Term Outcomes from Phase IIb Study of Eteplirsen

MDA Invites Public To Vote For Their Favorite Telethon Moment

DMD: FDA Gives Fast Track Designation to HT-100

HT-100, an experimental drug being developed for Duchenne muscular dystrophy (DMD) with support from MDA, has shown preliminary safety and signs of the desired effects on scar tissue formation in the first 17 trial participants, and it has received "fast track" designation from the U.S. Food and Drug Administration (FDA).